In addition, sodium-glucose cotransporter-2 (SGLT2) inhibitors are hypoglycemic agents that promote urinary glucose excretion and have been reported to reduce the development of nephropathy as well as cardiovascular disease in several large clinical trials9–11. The gene discussed is SLC5A2; the disease is cardiovascular disorder.